BioSapien (Pre-Series A)
Funding Details
- Awarder
- Inbox
- Date Award
- December 12, 2024
- Vertical
- Healthcare
- Funding URL
- View Funding Page
- Funding Amount:
- $5,500,000
Company Info
- Traction
- Patient trials are set to commence in the second quarter of 2025, with plans to expand the platform to other cancers and non-cancer indications.
- Founders
- Khatija Ali
- Company Description
- BioSapien is a drug delivery platform specializing in localized cancer treatment, focusing on minimizing systemic side effects through its flagship product, MediChip, a 3D-printed slow-release delivery platform.
- Market
- Cancer Treatment
- Location
- Abu Dhabi, UAE
- Coinvestors
- Global Ventures, Dara Holdings